FDA approves new drug for acute myeloid leukemia

mylotrag treatment acute myeloid leukemia

On Sept. 1, the U.S. Food and Drug Administration (FDA) approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML) and for he treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or are refractory to initial treatment.

Via FDA.gov

fda mylotrag treatment acute myeloid leukemia

 

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here